Research Paper Volume 15, Issue 23 pp 13646—13654
Cabozantinib prevents AGEs-induced degradation of type 2 collagen and aggrecan in human chondrocytes
Figure 6. Cabozantinib upregulated SOX-9 in AGEs-treated SW1353 chondrocytes. SW1353 chondrocytes were stimulated with 100 μg/ml AGEs with or without 10 and 20 μM Cabozantinib for 24 h. (A) mRNA level of SOX-9. (B) Protein level of SOX-9 (n=6, *, ** P<0.05, 0.01 vs. Control group, #, ## P<0.05, 0.01 vs. AGEs group).